全文获取类型
收费全文 | 2029篇 |
免费 | 96篇 |
国内免费 | 9篇 |
专业分类
耳鼻咽喉 | 18篇 |
儿科学 | 19篇 |
妇产科学 | 102篇 |
基础医学 | 305篇 |
口腔科学 | 10篇 |
临床医学 | 132篇 |
内科学 | 628篇 |
皮肤病学 | 7篇 |
神经病学 | 90篇 |
特种医学 | 41篇 |
外科学 | 291篇 |
综合类 | 10篇 |
预防医学 | 11篇 |
眼科学 | 97篇 |
药学 | 120篇 |
中国医学 | 1篇 |
肿瘤学 | 252篇 |
出版年
2023年 | 9篇 |
2022年 | 19篇 |
2021年 | 28篇 |
2020年 | 13篇 |
2019年 | 34篇 |
2018年 | 31篇 |
2017年 | 18篇 |
2016年 | 33篇 |
2015年 | 42篇 |
2014年 | 55篇 |
2013年 | 73篇 |
2012年 | 114篇 |
2011年 | 131篇 |
2010年 | 70篇 |
2009年 | 59篇 |
2008年 | 129篇 |
2007年 | 119篇 |
2006年 | 144篇 |
2005年 | 118篇 |
2004年 | 119篇 |
2003年 | 153篇 |
2002年 | 124篇 |
2001年 | 71篇 |
2000年 | 72篇 |
1999年 | 46篇 |
1998年 | 13篇 |
1997年 | 19篇 |
1996年 | 8篇 |
1995年 | 12篇 |
1994年 | 8篇 |
1993年 | 13篇 |
1992年 | 28篇 |
1991年 | 18篇 |
1990年 | 12篇 |
1989年 | 20篇 |
1988年 | 15篇 |
1987年 | 11篇 |
1986年 | 13篇 |
1985年 | 10篇 |
1984年 | 11篇 |
1983年 | 11篇 |
1982年 | 5篇 |
1978年 | 8篇 |
1973年 | 6篇 |
1972年 | 9篇 |
1971年 | 6篇 |
1970年 | 6篇 |
1969年 | 8篇 |
1968年 | 5篇 |
1966年 | 8篇 |
排序方式: 共有2134条查询结果,搜索用时 10 毫秒
31.
Matsubara S Izumi A Nagai T Kikkawa I Suzuki M 《Archives of gynecology and obstetrics》2008,278(2):195-197
BACKGROUND: While vaginal breech delivery, although rare, can cause femur fracture, abdominal breech delivery is not expected to cause it. CASE: A 2,490-g female infant was delivered at term by elective cesarean section for breech presentation. She sustained a fracture of the femur shaft. A simple splinting led to a complete healing of the fracture without sequelae. CONCLUSION: Although abdominal breech delivery reduces the risk of birth trauma, we must be aware that femur fracture can occur regardless of the mode of delivery. 相似文献
32.
Sumigama S Itakura A Yamamoto T Nagasaka T Yamamoto E Ino K Kikkawa F 《Gynecologic and obstetric investigation》2007,64(4):228-231
Twin pregnancy consisting of a complete hydatidiform mole (CHM) along with a live co-existing fetus is a rare entity and difficult to diagnose. A 37-year-old Japanese woman demonstrated a living fetus, a placenta and a multicystic mass within one gestational sac on ultrasound at 10 weeks. Termination of the pregnancy was performed, and the specimen was classified as partial mole by macro- and microscopic findings. The karyotype of the molar tissue was 46XX. DNA polymorphism analysis demonstrated that fetal DNA showed bi-parental origin while molar DNA showed paternal origin only. Thus, this case was erroneously classified by ultrasonography, macroscopic and pathologic findings, then correctly diagnosed as a twin pregnancy with a CHM and co-existing normal twin fetus by DNA polymorphism analysis. Immunohistochemistry of p57(KIP2), the paternally imprinted and maternally expressed gene, supported the genetic diagnosis. This case suggested that conventional diagnostic methods were inadequate for accurate diagnosis of CHM with a co-existing fetus. DNA polymorphism analysis should be requested for the diagnosis of hydatidiform mole, especially in cases where it is difficult to discriminate between partial hydatidiform mole and CHM with a co-existing fetus. 相似文献
33.
Eiko Hasegawa Masahiro Kobayashi Yusuke Kawamura Hiromi Yatsuji Hitomi Sezaki Tetsuya Hosaka Norio Akuta Fumitaka Suzuki Yoshiyuki Suzuki Yasuji Arase Kenji Ikeda Hiromitsu Kumada 《Hepatology research》2007,37(10):793-800
Background: We assessed the efficacy and anticarcinogenic effects of interferon (IFN) therapy in patients with hepatitis C virus (HCV)-related cirrhosis. Methods: The study subjects were 123 Japanese patients with HCV-related cirrhosis with genotype 1b low viral load or genotype 2 who received IFN from 1989 to 2005 (18 patients continue to receive IFN therapy). They included 81 men and 42 women aged 29-74 years (median, 56 years). Results: Univariate analysis identified four parameters that significantly influenced SVR; viral load (low HCV concentration, P < 0.001), duration of IFN therapy (>/= 52 weeks, P = 0.029), daily dose of IFN (>/= 6 million units, P = 0.018), induction therapy (presence, P = 0.010) and choline esterase (> 1.0 DeltapH, P = 0.037). Multivariate analysis identified viral load (risk ratio = 6.329, P < 0.001) and daily dose of IFN (risk ratio = 2.62, P = 0.042) as two independent parameters thatinfluenced SVR. During the observation period, newly developed hepatocellular carcinoma (HCC) was detected in 22 patients. The rates of development of HCC in patients with SVR were 5.8% at the fifth year and 10.3% at the 10th year, compared with 25.8% at the fifth year and 42.5% at the 10th year in non-SVR patients. Multivariate analysis showed that IFN efficacy (SVR) was the only independent factor of hepatocarcinogenesis (hazard ratio: 0.185, 95% confidence interval: 0.042-0.810, P = 0.025) Conclusion: Among patients with HCV-related cirrhosis, the rate of development of HCC is significantly less in patients with SVR. 相似文献
34.
Mitsunobu Kitamura Noritake Hata Tadateru Takayama Atsushi Hirayama Masashi Ogawa Akira Yamashina Hisaaki Mera Hideaki Yoshino Fumitaka Nakamura Yoshihiko Seino 《Heart and vessels》2016,31(6):907-917
This multicenter prospective study was conducted to assess high-sensitivity troponin T (hs-TnT) and other biomarkers to decide and predict culprit lesions indicated for emergency percutaneous coronary intervention (PCI) in patients with suspicious acute coronary syndrome (ACS). We have reported Hs-TnT is the most sensitive biomarker for earlier diagnosis and decision making in patients with suspected ACS. In this study, we had conducted subanalysis investigating the usefulness for prediction of ACS culprit lesion. The patients with suspicious ACS and initially negative whole-blood rapid troponin T test, who underwent coronary angiogram (CAG), were enrolled (n = 74). Hs-TnT, quantitative assay for conventional troponin T (c-TnT), creatine kinase MB isozyme (CK-MB), and heart-type fatty acid-binding protein (H-FABP) were simultaneously measured. ACS culprit lesion was described as total occlusion, subtotal occlusion, and/or angiographical unstable lesion such as thrombosis, ulceration or irregularity. The CAG revealed that 49 cases had ACS lesions to be indicated for emergency PCI. The areas under the ROC curves and ROC-optimized cut-off of hs-TnT, c-TnT, CK-MB, and H-FABP were 0.75, 0.67, 0.68, and 0.75, respectively, and 18, 11, 2.0, and 4.6 ng/ml, respectively. In patients with total occlusion and 90–99 % of diameter stenosis (TIMI 2 or 3), hs-TnT could predict emergency PCI with significantly higher sensitivity compared with H-FABP (hs-TnT >14 ng/ml; 71 %, and H-FABP >6.2 ng/dl; 51 %, p = 0.021) and other biomarkers. Meanwhile, H-FABP displayed significant correlations with number of diseased vessels and presence of thrombotic lesion. The present study first revealed different characteristics of correlation between the angiographic culprit lesions and each cardiac biomarker. For prediction of ACS lesions requiring emergency PCI, hs-TnT had the highest sensitivity with satisfied analytical precision. 相似文献
35.
36.
Takigawa T Yasuda H Terada M Haneda M Kashiwagi A Saito T Saida T Kitasato H Kikkawa R 《Internal medicine (Tokyo, Japan)》2000,39(2):123-127
OBJECTIVE: To determine the possible role of anti-GM1 ganglioside antisera from patients with Gullain-Barr*e syndrome (GBS) or chronic inflammatory demyelinating polyneuropathy (CIDP) in the development of nerve dysfunction. METHODS: The effect of the anti-GM1 antibody positive antisera obtained from 4 GBS patients and 1 CIDP patient on membrane potential and ionic currents in rat single myelinated nerve fibers was investigated using the voltage clamp technique and compared with that of the anti-GM1 negative antisera obtained from 3 healthy controls and 2 GBS patients. RESULTS: In the presence of active complement, anti-GM1 positive antisera from 5 patients including 4 GBS patients and 1 CIDP patient significantly suppressed Na+ current more than anti-GM1 negative antisera. CONCLUSION: This study supports the notion that anti-GM1 antibody is one of the causative factors of conduction abnormality in GBS patients. 相似文献
37.
Kayoko Kasuya Yusuke Kawamura Masahiro Kobayashi Junichi Shindoh Yuta Kobayashi Akira Kajiwara Soichi Iritani Shunichiro Fujiyama Tetsuya Hosaka Satoshi Saitoh Hitomi Sezaki Norio Akuta Fumitaka Suzuki Yoshiyuki Suzuki Kenji Ikeda Yasuji Arase Yuichiro Eguchi Masaji Hashimoto Hiromitsu Kumada 《Internal medicine (Tokyo, Japan)》2021,60(3):345
Objective A survival benefit was demonstrated for ramucirumab (RAM) in patients with unresectable hepatocellular carcinoma (uHCC) and α-fetoprotein (AFP) concentrations ≥400 ng/mL who had previously received sorafenib (SOR). However, it is unclear whether RAM has a similar efficacy in patients with uHCC that progresses after lenvatinib (LEN) treatment. This study aimed to evaluate the early anti-tumor response to RAM as a second-line treatment for advanced uHCC after LEN treatment. Methods We retrospectively assessed the efficacy and safety of RAM at 6 weeks after initiation. The therapeutic effects were evaluated according to the Response Evaluation Criteria in Solid Tumors version 1.1. Patients We evaluated 7 patients with uHCC who received RAM as a second- or third-line treatment after LEN failure. Results The disease control rate (DCR) was 28.6% (2 of 7 patients). After the initiation of RAM, a rapid disease progression resulted in 1 patient death after 19 days. The median progression-free survival (PFS) was 41 days. There were no grade 3 or 4 treatment-related adverse events. At 6 weeks, there was no deterioration in the modified albumin-bilirubin (mALBI) grade. In patients with an imaging response of stable disease (SD), the rate of AFP production decreased from the baseline. Conclusion RAM may have a therapeutic potential for the suppression of uHCC progression in patients previously treated with LEN, as well as for maintaining the liver function during treatment. Evaluating the AFP trends may therefore be useful for predicting RAM effectiveness. 相似文献
38.
Vipoma of the Pancreas Complicating Ulcerative Colitis 总被引:2,自引:0,他引:2
Hidenori Yanagi M.D. Masato Kusunoki M.D. Youichirou Sakanoue M.D. Yasutsugu Shoji M.D. Takehira Yamamura M.D. Masami Murai M.D. Nobuteru Kikkawa M.D. Joji Utsunomiya M.D. 《The American journal of gastroenterology》1991,86(8):1066-1069
We report a case of vipoma of the pancreas in conjunction with ulcerative colitis in a 20-yr-old woman. Twenty months after the onset of ulcerative colitis, the patient complained of watery diarrhea and was found to have an electrolyte disorder. A pancreatic tumor was detected by ultrasonography and computed tomography, along with an elevation of serum vasoactive intestinal polypeptide (VIP). The secretory diarrhea diminished dramatically, and the serum VIP level decreased into the normal range immediately after resection of the pancreatic tumor. Immunohistochemical staining revealed a pancreatic vipoma. Despite removal of the vipoma, she underwent restorative proctocolectomy and ileal J-pouch anal anastomosis 2 yr later due to progression of the ulcerative colitis. Postoperative course was uneventful, with excellent functional results. Knowledge of this rare condition accompanying ulcerative colitis may help in the management of the patient with an atypical clinical course. 相似文献
39.
Maegawa H Obata T Shibata T Fujita T Ugi S Morino K Nishio Y Kojima H Hidaka H Haneda M Yasuda H Kikkawa R Kashiwagi A 《Diabetologia》1999,42(2):151-159
Summary A newly synthesized antidiabetic agent, JTT-501 is an isoxazolidinedione rather than a thiazolidinedione. An oral dose of
JTT-501 (100 mg · kg–1· day–1) given to 12-week-old male Zucker fatty rats for 7 days led to the amelioration of both hyperinsulinaemia (40 % of non-treated)
and hypertriglyceridaemia (23 % of non-treated) as well as a 2.4-fold increased insulin sensitivity as determined by a euglycaemic
insulin clamp. In our study, we further evaluated the acute effect of JTT-501 on both the glucose infusion rates (GIR) and
insulin signalling in skeletal muscle. Male Sprague-Dawley (SD) rats aged 10 weeks were injected intravenously with JTT-501
(5 mg/kg) and then a euglycaemic insulin clamp was initiated and glucose infusion rates monitored for 150 min. We found that
this treatment increased the glucose infusion rate by 33 % during the last 30 min in SD rats. After the clamp had been initiated
for 30 min, the insulin-stimulated phosphatidylinositol 3-kinase (PI3-kinase) activities co-immunoprecipitated with insulin
receptor substrate 1 (IRS-1) were also enhanced, resulting in increased glycogen synthase activities in the soleus muscles.
Treatment with JTT-501 also enhanced the phosphorylation of insulin receptors and insulin receptor-substrate 1 rapidly as
well as the phosphatidylinositol 3-kinase activities, which were stimulated by a bolus injection of insulin. Similarly, JTT-501
stimulated the glucose infusion rate by 30 % and enhanced insulin signalling in Zucker fatty rats. In conclusion, a newly
developed isoxazolidinedione, JTT-501, rapidly potentiates the insulin sensitivity of skeletal muscle by enhancing insulin
signalling and could be useful for the treatment of insulin-resistant diabetic subjects. [Diabetologia (1999) 42: 151–159]
Received: 2 June 1998 and in final revised form: 2 October 1998 相似文献
40.
Norio Akuta Fumitaka Suzuki Taito Fukushima Yusuke Kawamura Hitomi Sezaki Yoshiyuki Suzuki Tetsuya Hosaka Masahiro Kobayashi Tasuku Hara Mariko Kobayashi Satoshi Saitoh Yasuji Arase Kenji Ikeda Hiromitsu Kumada 《Journal of clinical microbiology》2013,51(9):2862-2868
It is often difficult to predict the response to telaprevir-pegylated interferon (PEG-IFN)-ribavirin triple therapy and the appearance of telaprevir-resistant variants. The present study determined the predictive factors of a sustained virological response (SVR) to 12- or 24-week triple therapy (T12PR12 or T12PR24, respectively) in 194 Japanese patients infected with hepatitis C virus genotype 1b (HCV-1b). The study also evaluated whether ultradeep sequencing technology can predict at baseline the emergence of resistant variants after the start of therapy. Analysis of the data of the entire group indicated that an SVR was achieved in 78% of the patients. Multivariate analysis identified IL28B rs8099917 (genotype TT), the substitution of amino acid (aa) 70 (Arg70), response to prior treatment (naive or relapse), PEG-IFN dose (≥1.3 μg/kg of body weight), and treatment regimen (T12PR24) as significant determinants of SVR. Among patients of the T12PR24 group, 92% with genotype TT achieved an SVR, irrespective of a substitution at aa 70. In patients with the non-TT genotype, an SVR was achieved in 76% of those with Arg70, while only 14% of patients with the non-TT genotype, Gln70(His70), and nonresponse to ribavirin combination therapy achieved an SVR. Ultradeep sequencing was conducted for 17 patients who did not achieve an SVR to determine the emergence of resistant variants during therapy. De novo resistant variants were detected in 16 of 17 patients (94%), regardless of the variant frequencies detected at baseline. In conclusion, the results indicate that the response to triple therapy can be predicted by the combination of host, viral, and treatment factors and that it is difficult to predict at baseline the telaprevir-resistant variants that emerge during triple therapy, even with the use of ultradeep sequencing. 相似文献